A clinical trial update was recorded on August 21, 2026, for a study involving gocatamig (MK-6070) and infinatamab deruxtecan (MK-2400) in people with small cell lung cancer.
The trial, titled "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)," is registered under identifier NCT07227597.
The study is listed as Phase 1/Phase 2 and its current status is recruiting. No results have been posted for this trial as of this update.
This news brief reports only the status change and administrative details as reflected in the trial registry entry. No efficacy or safety outcomes are described in this update, and none should be inferred from the recruiting status alone.
Substance P, referenced in connection with this update, remains classified as an unapproved research compound. It has not been approved for clinical use in this or any other indication described here.
Readers interested in background information can consult the compound overview for additional context on substance P.